Over 6 million people in the US are living with Alzheimer disease (AD)1, and over 80 million adults between 50-70 years whose biggest health fear, other than cancer, is AD2.
We want to help them all.
Labcorp is working hard, combining the power of new high precision technology with artificial intelligence to advance diagnostic testing in order to provide clear, objective answers to clinicians, patients, and families.
We are working with blood-based biomarkers, like pTau and NfL, and collaborating with pharmaceutical and diagnostic partners to develop tests that identify, diagnose and monitor patients with AD.
Neurofilament Light Chain (NfL) Test (140455)
NfL is a well-studied blood biomarker test that is now widely available through Labcorp for assessing neuronal damage from neurodegenerative diseases and sports-related concussion.
LabCorp’s Beta-Amyloid 42/40 Ratio test quantifies the amount of beta-amyloid 42 and 40 proteins in a CSF patient sample and computes the ratio of those proteins, providing an indication of disease progression. Studies have shown strong correlation of CSF beta-amyloid levels to PET scan results. This test can be a surrogate to more costly PET scan imaging.
This test detects the presence of the Apolipoprotein E (APOE)-4 variant, which is associated with increased risk of late-onset (age >60-65) Alzheimer's disease (AD). Testing may be considered for patients with dementia to supplement information from clinical and other evaluations. APOE has multiple roles, including lipid transport in the blood and the brain. The APOE4 variant increases the risk for late-onset Alzheimer's disease and may contribute to the pathology of the disease through influence on β-amyloid, inflammation, or other processes.
Early Onset Alzheimer's NGS Diagnostic Test (630557)
AD is a complex and heterogeneous disease, influenced by many genetic and environmental factors. Early onset familial AD (presenting between 25-60) occurs in less than 2% of AD cases. This test analyzes three genes (amyloid protein precursor (APP), presenilin 1 (PSEN1) and presenilin 2 (PSEN2)) to detect pathogenic variants that cause autosomal dominant early onset Alzheimer's disease. Testing may be considered to confirm a diagnosis of early onset Alzheimer's disease in symptomatic individuals.
Anderson LA, Day KL, Beard RL, et.al. “The Public's Perceptions About Cognitive Health and Alzheimer's Disease Among the U.S. Population: A National Review”. The Gerontologist. 2009; 49(S1): S3–S11.
1. Palmqvist S, Zetterberg H, Mattsson N, et.al. “Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease.” Neurology. 2015;85:1–10
2. Hansson O, Seibyl J, Stomrud E, et.al. “CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts.” Alzheimer’s & Dementia. 2018; 14(11): P1470-1481.
Explore More Neurodegenerative Capabilities
ALS, Ataxias, & Huntington's
Genetics can play a significant role in the development of certain neurodegenerative diseases. In some cases, genetic testing may help confirm a diagnosis.